EAGLE PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (EGRX)

Historical Holders from Q1 2014 to Q1 2025

Symbol
EGRX on OTC
CUSIP
269796108
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
13M
All holders as of December 31, 2024
Q4 2024
Shares, excl. options
79.1K
Holdings value
$39.1K
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
10
Number of buys
2
Number of sells
-55
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of EAGLE PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (EGRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Nantahala Capital Management, LLC 38.08% $4.85M 4.95M Nantahala Capital Management, LLC Feb 16, 2025
Union Square Park Capital Management, LLC 11.44% $1.46M 1.49M Union Square Park Partners, LP Dec 31, 2024
Nantahala Capital Partners Limited Partnership 6.24% $794K 811K NANTAHALA CAPITAL PARTNERS LIMITED PARTNERSHIP Feb 16, 2025

Institutional Holders of EAGLE PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (EGRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q1 12K $11.8K -$18 $0.98 1
2024 Q4 79.1K $39.1K -$31.4M $0.50 10
2024 Q3 8.56M $31.9M -$6.51M $3.73 64
2024 Q2 9.91M $55.5M -$2.73M $5.60 74
2024 Q1 10.5M $54.8M +$2.03M $5.24 91
2023 Q4 10M $52.4M -$17.2M $5.23 101
2023 Q3 10.3M $163M -$8.1M $15.77 105
2023 Q2 10.8M $209M -$25.9M $19.44 120
2023 Q1 11.8M $334M +$6.36M $28.37 152
2022 Q4 11.6M $338M +$2.94M $29.23 151
2022 Q3 9.35M $247M -$9.39M $26.42 137
2022 Q2 11.4M $500M +$17.1M $44.43 154
2022 Q1 10.9M $541M +$1.11M $49.49 151
2021 Q4 10.9M $554M -$54.7M $50.92 154
2021 Q3 11.8M $659M -$12.8M $55.78 147
2021 Q2 11.9M $508M -$4.78M $42.80 137
2021 Q1 12.1M $505M -$2.42M $41.74 149
2020 Q4 12.2M $570M -$4.95M $46.57 156
2020 Q3 12.3M $521M -$21M $42.48 160
2020 Q2 12.9M $619M -$12.6M $47.98 158
2020 Q1 13.2M $607M -$10.2M $46.00 163
2019 Q4 13.1M $788M +$6.08M $60.08 173
2019 Q3 13.2M $745M -$18.9M $56.57 180
2019 Q2 13.5M $752M +$26.5M $55.68 176
2019 Q1 13.2M $665M -$20.2M $50.49 172
2018 Q4 13.9M $560M -$99M $40.29 174
2018 Q3 15.1M $1.05B +$1.47M $69.33 183
2018 Q2 15.3M $1.16B -$22.9M $75.66 177
2018 Q1 15.7M $825M -$8.76M $52.69 168
2017 Q4 15.8M $846M +$1.8M $53.42 163
2017 Q3 15.7M $939M -$210M $59.64 162
2017 Q2 15.3M $1.21B +$310M $78.89 167
2017 Q1 16.4M $1.36B +$101M $82.94 144
2016 Q4 16.5M $1.31B -$58.1M $79.34 146
2016 Q3 16.7M $1.17B +$53.7M $70.00 134
2016 Q2 17.1M $665M +$58M $38.79 112
2016 Q1 15.7M $634M -$1.1M $40.50 115
2015 Q4 14.9M $1.32B +$76.4M $88.67 130
2015 Q3 14M $1.04B +$40.4M $74.03 116
2015 Q2 13.4M $1.08B +$143M $80.86 118
2015 Q1 11.7M $489M +$142M $41.89 68
2014 Q4 9.2M $143M +$21.8M $15.50 28
2014 Q3 2.97M $37.6M +$13.8M $12.65 24
2014 Q2 1.74M $24.9M -$1.57M $14.33 27
2014 Q1 1.91M $24.4M +$24.4M $12.75 28